Afuco™ Anti-KIRD2 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-757) (CAT#: AFC-TAB-757)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human monoclonal antibody expressed in CHO binding to human KIRD2 subgroup. It is a human monoclonal antibody designed for the treatment of cancer.
Specific Inquiry
Custom Production
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.
We require custom production
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Human
- Derivation
- Human
- Type
- ADCC enhanced antibody
- Species Reactivity
- Human
- Applications
- Neut, ELISA, IF, IP, FuncS, FC
- Conjugate
- Unconjugated
- Generic Name
- Lirilumab
- Related Disease
- Acute myeloid leukemia (AML)
Product Property
- Purity
- >95% by SDS-PAGE
- Storage
- Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Target
- Alternative Names
- Killer-cell immunoglobulin-like receptors; KIRs; KIR2DL1/2/3
Related Resources
Please refer to Lirilumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Lirilumab.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Lirilumab"
DrugMonitor™ Anti-Lirilumab Antibody (VS-1224-YC676)Lirilumab is a human monoclonal antibody designed for cancer treatment by binding to KIR2DL1/2/3, evaluated in trials for conditions including leukemia, multiple myeloma, and acute myeloid leukemia. The DrugMonitor™ Anti-Lirilumab Antibody (VS-1224-YC676) is an anti-drug antibody (ADA) against Lirilumab. This drug-based antibody is raised in mice immunized with the Lirilumab. The anti-Lirilumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Lirilumab in samples.
Customer Reviews and Q&As
There are currently no Customer reviews or questions for AFC-TAB-757. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: WB, IP, IF, FuncS, FC, Neut, ELISA
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
-2.jpg)
Application: IB, ELISA, FC, FuncS
Application: Neut, Inhib, FC, ELISA
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: ELISA, FC, IF, IHC, WB
-2.png)
Application: ELISA, WB
Application: ELISA, IHC, IF, IP
Application: Inhib, FC, WB
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
